SCHEMBL24252277

SCHEMBL24252277

Cc1nnc(N)c2ccc(-c3cc(B(O)O)ccc3C(F)(F)F)cc12

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 1/20 0.34
SCN9A Q15858 3/20 0.33
SCN5A Q14524 1/20 0.33
PLG P00747 1/20 0.33
F12 P00748 1/20 0.33
F11 P03951 1/20 0.33
KLKB1 P03952 1/20 0.33
PRSS1 P07477 1/20 0.33
PRSS2 P07478 1/20 0.33
PRSS3 P35030 1/20 0.33
AR P10275 1/20 0.32
BACE1 P56817 1/20 0.30
CYP3A4 P08684 2/20 0.30
CYP2D6 P10635 2/20 0.30
USP2 O75604 1/20 0.30
ALDH1A1 P00352 1/20 0.30
CYP1A2 P05177 1/20 0.30
TSHR P16473 1/20 0.30
MAPK1 P28482 1/20 0.30
CYP2C19 P33261 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Formic Acid SCHEMBL25239177 0.95 AR (0.31) TRPA1SCN9ASCN5APLGF12
Formic Acid SCHEMBL30451910 0.95 AR (0.31) TRPA1SCN9ASCN5APLGF12
SCHEMBL25239175 0.86 AR (0.31) TRPA1SCN9ASCN5AAR
SCHEMBL24252506 0.84 MAP4K4 (0.37) PLGF12F11KLKB1PRSS1
SCHEMBL24252263 0.84 MAP4K4 (0.37) PLGF12F11KLKB1PRSS1
SCHEMBL30451527 0.84 SCN9A (0.31) SCN9ASCN5A
SCHEMBL24252662 0.84 SCN9A (0.31) SCN9ASCN5A
SCHEMBL24252504 0.83 SCN9A (0.36) SCN9ASCN5APLGF12F11
SCHEMBL30452320 0.83 SCN9A (0.36) SCN9ASCN5APLGF12F11
SCHEMBL24252343 0.83 KIF11 (0.33) PLGF12F11KLKB1PRSS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 TRPA1 2579/4885SCN9A 3732/4885SCN5A 3532/4885
US-11814404-B2 Inhibitors of complement factors and uses thereof CFB, CFH, C9 TRPA1 2579/4885SCN9A 3732/4885SCN5A 3532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.